Norge - norsk - Statens legemiddelverk

medice arzneimittel pütter gmbh & co kg - atomoksetinhydroklorid - tablett, filmdrasjert - 100 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

bioprojet pharma - pitolisant - sleep apnea, obstructive - andre nervesystemet narkotika - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).

Norge - norsk - Statens legemiddelverk

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 10 mg

Norge - norsk - Statens legemiddelverk

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 18 mg

Norge - norsk - Statens legemiddelverk

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 25 mg

Norge - norsk - Statens legemiddelverk

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 40 mg

Norge - norsk - Statens legemiddelverk

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 60 mg

Norge - norsk - Statens legemiddelverk

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 80 mg

Norge - norsk - Statens legemiddelverk

medical valley invest ab - atomoksetinhydroklorid - kapsel, hard - 100 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.